Proteins CNTF , Human
- Known as:
- Proteins CNTF , Human
- Catalog number:
- C098
- Product Quantity:
- 10μg
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Proteins CNTF Human
Related genes to: Proteins CNTF , Human
- Gene:
- CNTF NIH gene
- Name:
- ciliary neurotrophic factor
- Previous symbol:
- -
- Synonyms:
- HCNTF
- Chromosome:
- 11q12.1
- Locus Type:
- gene with protein product
- Date approved:
- 1991-01-07
- Date modifiied:
- 2016-10-05
Related products to: Proteins CNTF , Human
Related articles to: Proteins CNTF , Human
- Ciliary neurotrophic factor (CNTF) is a neurotrophic cytokine involved in neuronal survival, synaptic plasticity, and retinal ganglion cell health, and it correlates with different stages of cognitive impairment. Mild cognitive impairment (MCI) is difficult to diagnose, as these patients perform normally on standardized cognitive tests. It is important to diagnose patients with MCI early to prevent its progression and to maintain their quality of life. Alterations in retinal morphology mirror central nervous system pathology, including cognitive impairment. This cross-sectional study investigates the association between retinal structural changes and plasma CNTF levels and assesses their possible clinical value for screening early cognitive impairment. Retinal morphology was assessed by optical coherence tomography (OCT), and plasma CNTF was measured by enzyme-linked immunosorbent assay (ELISA) in 69 healthy participants. We correlated retinal biomarkers and CNTF levels with cognitive function as measured by the Montreal Cognitive Assessment (MoCA). CNTF levels were significantly higher in the low MoCA group (median = 287.6, IQR: 235.90-359.7) compared to the normal cognition group (median = 185.90, IQR: 162.1-277.5) ( < 0.001). Average central thickness and retinal nerve fiber layer (RNFL) were positively associated with CNTF ( < 0.05). Our results indicate that CNTF is negatively associated with cognition and positively correlated with RNFL and average central thickness. Screening for MCI with non-invasive OCT imaging and plasma CNTF may aid in the early detection of cognitive impairment. Future pharmacological interventions with CNTF analogs may preserve or even restore cognitive function. - Source: PubMed
Publication date: 2026/09/21
Al-Mazidi SarahAl-Ayadhi Laila - Macular telangiectasia type 2 (MacTel), a bilateral, neurodegenerative disease associated with photoreceptor loss, often leads to progressive scotomas, metamorphopsia, and impaired reading function. Revakinagene taroretcel-lwey, a Food and Drug Administration (FDA)-approved encapsulated cell-based therapy for adults with MacTel, is surgically inserted into the vitreous cavity and provides sustained intraocular delivery of recombinant human ciliary neurotrophic factor (CNTF). Results from two phase 3 randomized clinical trials support the efficacy and safety of revakinagene taroretcel-lwey; explant analyses have demonstrated bioactive CNTF release up to 14.5 years. This report summarizes the surgical procedure and techniques for revakinagene taroretcel-lwey implantation, including implant preparation, insertion, wound closure, and postoperative procedures, and highlights scenarios where expert guidance may help to prevent intraoperative errors and minimize the potential for postsurgical adverse events. Standardizing surgical steps and incorporating expert guidance into surgical technique may reduce adverse events, including migration and extrusion, wound leaks, and infections, supporting safe long-term CNTF delivery for treatment of MacTel. - Source: PubMed
Publication date: 2026/09/23
Goldberg Roger AWykoff Charles CSutherland Liliya - Efficient axonal transport is essential for maintaining neuronal function, enabling the bidirectional delivery of diverse cargoes between the cell body and distal compartments. In the neuromuscular system, neurotrophic factors regulate motor neuron survival, function and synaptic connectivity, in part, through retrograde trafficking of activated neurotrophic factor-receptor complexes from the neuromuscular junction to the cell body. We recently demonstrated that brain-derived neurotrophic factor stimulation to muscles selectively enhances retrograde transport of signalling endosomes in fast, but not slow, motor neurons . Moreover, both axonal endosome transport and its brain-derived neurotrophic factor-mediated regulation are disrupted in mouse models of diseases impacting motor neurons, including amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease. Here, we examined whether additional neurotrophic factors, when applied to distal axon terminals, share this transport-modulating property. Through imaging sciatic nerves in anaesthetised mice, we tracked the dynamics of signalling endosomes in fast and slow motor neurons via intramuscular injections of a fluorescent atoxic fragment of tetanus neurotoxin. These injections were co-administered with ciliary neurotrophic factor, hepatocyte growth factor, neurturin, or cleavage-resistant pro-brain-derived neurotrophic factor-four growth factors with known effects on motor neurons. Compared to vehicle-treated controls, pro-brain-derived neurotrophic factor, hepatocyte growth factor and neurturin produced no detectable change in transport dynamics. In contrast, ciliary neurotrophic factor markedly reduced endosome speeds in both fast and slow motor neurons, indicating remarkable selectivity of specific neurotrophic factors in the regulation of signalling endosome transport in motor neurons. Understanding this selectivity may aid the development of muscle-targeted neurotrophic factor-based therapeutic strategies aimed at restoring axonal transport in neurodegenerative disease, peripheral neuropathy and nerve injury. - Source: PubMed
Publication date: 2026/09/05
Rhymes Elena RFetkowitz CassandraSchiavo GiampietroSleigh James NTosolini Andrew P - The use of autologous growth factors, such as those contained in Hypoxia-Preconditioned Serum (HPS) and Platelet-Rich Plasma (PRP), represents a promising strategy to enhance regenerative processes in injured nerves. As an initial study, we investigated the effects of these secretomes on the neuroblastoma cell line N2a. - Source: PubMed
Publication date: 2026/09/04
Jiang JunSafa DonyaKnoedler SamuelAltammar JannatFalkner FlorianHanschen MarcKükrek HaydarDornseifer UlfSchilling Arndt FMachens Hans-GüntherMoog Philipp - This study utilized micro-positron emission tomography/computed tomography (micro-PET/CT) to track the longitudinal and dynamic progression of cardiac autonomic nerve injury in diabetic rats. Our objective was to map the precise timeline of neural damage relative to disease stages, defining a sensitive imaging window for the early diagnosis of diabetic cardiac autonomic neuropathy (DCAN). - Source: PubMed
Publication date: 2026/09/07
Gu JingWang HuiHe Yulin